Retatrutide leads to significant weight loss with some reduction in lean mass, consistent with physiological weight-loss patterns
it requires moderation
GIP activation appears to improve fat oxidation and may have direct effects on adipose tissue that promote fat breakdown
The Availability of Compounded GLP-1 Some online compounding pharmacies have stopped marketing GLP-1 drugs in response to the FDA's announcement, or have pivoted and joined forces with GLP-1 manufacturers, now offering only the brand name anti-obesity medications
Contact your GP or prescriber promptly if you experience: Diarrhoea lasting more than 4872 hours without improvement Signs of dehydration, including dark urine, dizziness, dry mouth, or reduced urination dehydration can lead to acute kidney injury, particularly in people with pre-existing kidney conditions Blood or mucus in your stools, or rectal bleeding Severe or worsening abdominal pain, particularly if localised, persistent, or accompanied by fever Persistent vomiting that prevents you from keeping fluids down Rapid, symptomatic, or disproportionate weight loss accompanied by systemic symptoms such as fatigue or fever this is distinct from the expected gradual weight loss associated with treatment and should be discussed with your prescriber Symptoms that are substantially affecting your ability to work, sleep, eat, or carry out daily activities Seek urgent medical assessment if you develop: Severe, persistent abdominal pain particularly pain radiating to the back which may indicate pancreatitis
Beyond quantitative preservation, maintaining skeletal muscle function, including strength and metabolic capacity, remains a critical therapeutic goal in ensuring long-term health outcomes
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
